Clinical trials: Influenza, completed
Influenza
Vitamin D and the Influenza Epidemic
Subjects included in ongoing vitamin d intervention trials were asked by questionnaire if they were ill with influenza during the winter season 2009/2010 to see if vitamin d supplementation prevented flu like disease.
- Trial name
- NCT01182870
- Testing
- choleclaciferol
- Where
- Norway
- Volunteers
- 569 people, healthy volunteers welcome
- Sponsor
- University of Tromso
Cough, Myalgia
Clinical Evaluation of QFlu Combo Test
Currently effective antivials for influenza treatment are two influenza viral neuraminidase inhibitors, oseltamivir (Tamiflu) and zanamivir (Relenza).
- Conditions
- Cough, Myalgia, Nasal Obstruction, Sore Throat
- Trial name
- QFlu (NCT01506583)
- Where
- 3 sites in United States
- Volunteers
- 506 people
- Sponsor
- Cellex, Inc.
Observation Safety
Postmarketing Safety Study of Q/LAIV in Subjects 2 Through 49 Years of Age
This is an observational post-marketing study conducted in children and adults immunized with Q/LAIV as part of routine clinical practice at Kaiser Permanente Northern California (NCKP) sites.
- Trial name
- NCT01985997
- Where
- United States
- Volunteers
- 95,000 people, healthy volunteers welcome
- Sponsor
- MedImmune LLC
Influenza Immunization, Healthy Volunteers
Study of a Quadrivalent High-Dose Influenza Vaccine and a Moderna COVID-19 Vaccine Administered Either Concomitantly or Singly in Participants 65 Years of Age and Older Previously Vaccinated With a 2-dose Schedule of Moderna COVID-19 Vaccine
The main purpose of this Phase II study was to assess the safety and immunogenicity of a dose of Fluzone High-Dose (HD) Quadrivalent vaccine and a third dose or booster dose of Moderna coronavirus disease 19 (COVID-19) vaccine…
- Trial name
- NCT04969276
- Testing
- Quadrivalent Inactivated Influenza High Dose, COVID-19 mRNA Vaccine (nucleoside modified)
- Where
- 6 sites in United States
- Volunteers
- 306 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza A
Safety and Immunogenicity of the Bris10 M2SR and Sing2016 M2SR H3N2 Monovalent Influenza Vaccines
This is a Phase I double-blind, randomized, placebo-controlled study in 250 healthy adults, 18-49 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT03999554
- Testing
- LD Sing2016 M2SR H3N2 influenza vaccine, MD Sing2016 M2SR H3N2 influenza vaccine, HD Sing2016 M2SR H3N2 influenza vaccine
- Where
- 4 sites in United States
- Volunteers
- 206 people, healthy volunteers welcome
- Sponsor
- FluGen Inc
Seasonal Influenza Vaccination
Seasonal Influenza Vaccination Reminders for Children With High-risk Conditions
The objective of this study was to assess the feasibility and effectiveness of using a statewide immunization information system (IIS) to send seasonal influenza vaccine reminders from Local Health Departments (LHDs), targeting…
- Trial name
- NCT01431183
- Testing
- Mailed influenza vaccination reminder notice
- Where
- United States
- Volunteers
- 3,618 people
- Sponsor
- University of Michigan
Influenza
Oral Triple Combination Antiviral Drug Therapy for Treatment of Influenza A in Immunocompromised Subjects
This Phase 2, open label, randomized study will investigate the virologic benefit, clinical efficacy, safety, and tolerability of amantadine and ribavirin with oseltamivir (TCAD) versus oseltamivir monotherapy for the treatment…
- Trial name
- PO206 (NCT00979251)
- Testing
- Oseltamivir Phosphate, ADS-8902
- Where
- 25 sites in United States, Australia and 3 more
- Volunteers
- 2 people
- Sponsor
- Adamas Pharmaceuticals, Inc.
Influenza
Vaccine Health Literacy Related Text Message Reminders to Increase Receipt of Second Dose of Influenza Vaccine for Young, Low Income, Urban Children
Influenza remains a potentially significant and largely preventable source of morbidity and mortality, yet vaccine coverage is low.
- Trial name
- NCT01662583
- Testing
- Text Message, Written reminder
- Where
- United States
- Volunteers
- 660 people
- Sponsor
- Columbia University
Pertussis/Whooping Cough, Influenza Viral Infections
Influenza and Pertussis Vaccination Status of Women in Immediate Postpartum and Caregivers
Pertussis is a bacterial respiratory infection caused by Bordetella pertussis. Highly contagious, it is potentially serious and even fatal in infants under 6 months of age.
- Trial name
- COVAGRIP (NCT05234229)
- Testing
- Survey
- Where
- France
- Volunteers
- 254 people
- Sponsor
- Central Hospital, Nancy, France
Influenza
Safety and Immunogenicity of H1N1 Vaccines in Children Aged 6 Months to Less Than 9 Years of Age
The purpose of this study is to characterize the safety and immune response of the H1N1 (swine) flu vaccines GSK2340274A and GSK2340273A in children 6 months to less than 9 years of age.
- Trial name
- NCT00976820
- Testing
- GSK2340274A, GSK2340273A
- Where
- 30 sites in United States, Canada
- Volunteers
- 323 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Safety and Immunogenicity of Fluzone® Quadrivalent, Flublok® Quadrivalent, and Fluzone® High-Dose, Influenza Vaccines, 2018-2019 Formulations
The primary objectives of this study were: To describe the immunogenicity of the 2018-2019 formulation of Fluzone® Quadrivalent vaccine in children 6 to less than (<) 36 months of age and 3 to <9 years of age, and in adults 18 to…
- Trial name
- GRC90 (NCT03617523)
- Testing
- Fluzone Quadrivalent vaccine, 2018-2019 formulation, Flublok Quadrivalent vaccine, 2018-2019 formulation, Fluzone High-Dose vaccine, 2018-2019 formulation
- Where
- 3 sites in United States
- Volunteers
- 240 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza
Comparison of Immune Responses to Influenza Vaccine In Adults of Different Ages (SLVP015 2007-2017)
In this study the investigators are trying to understand how immune function declines in the elderly using annual influenza vaccinations as a model system. The longitudinal study began in 2007 and continued through early 2017.
- Trial name
- NCT01827462
- Testing
- Trivalent, inactivated influenza vaccine (TIV), Quadrivalent, inactivated influenza vaccine (IIV4), High-Dose Trivalent, inactivated influenza vaccine (TIV High-Dose)
- Where
- United States
- Volunteers
- 136 people, healthy volunteers welcome
- Sponsor
- Stanford University
Influenza Immunisation, Healthy Volunteers
Study of Recombinant Influenza Vaccine Containing Different H3 Antigens Without or With Adjuvant in Healthy Adult Subjects
The primary objectives of the study are: To describe the safety profile of the different formulations in all participants To describe the hemagglutinin inhibition (HAI) and seroneutralization (SN) antibody responses against…
- Trial name
- FBP00004 (NCT04451954)
- Testing
- Quadrivalent RIV with H3 strain 1, Quadrivalent RIV with H3 strain 1 and adjuvant, Quadrivalent RIV with H3 strain 2
- Where
- 5 sites in United States
- Volunteers
- 210 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Healthy
Galactooligosaccharide, Immune Strength, and Digestive Health in Older Adults Over Cold and Flu Season
The purpose of this research study is to determine whether a functional fiber, galactooligosaccharide, can help maintain immune strength and digestive health in free-living older adults.
- Trial name
- GOS (NCT01302561)
- Testing
- Sucrose, Galactooligosaccharide
- Where
- United States
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- University of Florida
Influenza
Safety and Immunogenicity Among Healthy Children Receiving Fluzone® Quadrivalent, Influenza Vaccine
The study will evaluate the safety and immunogenicity of the 2014-2015 formulation of Fluzone Quadrivalent vaccine, administered in a 1- or 2-dose schedule, in accordance with the Advisory Committee on Immunization Practices…
- Trial name
- NCT02222870
- Testing
- Fluzone® Quadrivalent Influenza Vaccine, No Preservative
- Where
- 2 sites in United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Influenza, Vaccination
Using Explainable AI Risk Predictions to Nudge Influenza Vaccine Uptake
The study team previously demonstrated that patients are more likely to receive flu vaccine after learning that they are at high risk for flu complications.
- Conditions
- Influenza, Vaccination, Health Promotion, Health Behavior
- Trial name
- NCT05009251
- Testing
- Reminder, Risk reduction, Medical records-based recommendation
- Where
- United States
- Volunteers
- 45,061 people
- Sponsor
- National Bureau of Economic Research, Inc.
Influenza
Reacto & Immunogenicity of TF Formulation of Influsplit SSW® 2002/03 v/s Std Formulation of Influsplit SSW® 2002/03
This is a comparative vaccination study of the reactogenicity and immunogenicity of a thiomersal-free formulation of Influsplit SSW® 2002/2003 versus the standard formulation of Influsplit SSW® 2002/2003 in individuals over 18…
- Trial name
- NCT00731029
- Testing
- Thiomersal free trivalent influenza split vaccine 2002/2003, GlaxoSmithKline Biologicals' Influsplit SSW®/Fluarix™ 2002/2003
- Where
- Germany
- Volunteers
- 239 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza
Immunogenicity and Safety Study to Evaluate Different Formulations of GSK Biologicals' Influenza Vaccine GSK576389A
In order to find the formulation leading to a maximal increase of the immune response while maintaining an acceptable safety profile, this study is designed to evaluate the immunogenicity, safety and reactogenicity of the…
- Trial name
- NCT00540592
- Testing
- GlaxoSmithKline Biologicals' influenza vaccine GSK576389A, Fluarix
- Where
- 30 sites in Germany, Netherlands and 2 more
- Volunteers
- 2,007 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Influenza, Human
Childhood Influenza Immunisation in General Practice Invitation Trial
This study will investigate whether behaviourally informed changes to the invitation process can improve uptake of childhood influenza vaccine by two and three year olds at primary care.
- Trial name
- NCT02921633
- Testing
- Intervention letter
- Volunteers
- 21,786 people, healthy volunteers welcome
- Sponsor
- Public Health England
Influenza A
Convalescent Plasma Treatment in Severe 2009 H1N1 Infection
Treatment of severe 2009 H1N1 infection with convalescent plasma will reduce mortality.
- Trial name
- NCT01306773
- Testing
- H1N1 convalescent plasma and oseltamivir, Oral Oseltamivir alone
- Where
- China
- Volunteers
- 80 people
- Sponsor
- The University of Hong Kong
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.